Table 1 Baseline patient characteristics
Normal AFP Trajectory Group (n = 128) | Abnormal AFP Trajectory Group (n = 11) | P-Value | |
|---|---|---|---|
Sex | |||
Male | 104(81.3%) | 7(63.6%) | 0.314 |
Female | 24(18.7%) | 4(36.4%) | |
Age (years) | 55.20 ± 9.39 | 56.36 ± 7.65 | 0.711 |
Baseline AFP (ng/mL) | 475.0(46.1–4963.0) | 1915.0(125.0–77125.0) | 0.132 |
Hepatitis | |||
Hepatitis B | 115(89.8%) | 11(100.0%) | 0.324 |
Hepatitis C | 2(1.6%) | 0 | |
Other | 11(8.6%) | 0 | |
PVT | |||
Present | 44(34.4%) | 6(54.5%) | 0.312 |
Absent | 84(65.6%) | 5(45.5%) | |
Extrahepatic Metastasis | |||
Present | 49(38.3%) | 5(45.5%) | 0.884 |
Absent | 79(61.7%) | 6(54.5%) | |
Child–Pugh Classification | |||
Level A | 91(71.0%) | 8(72.7%) | 1.000 |
Level B | 37(29.0%) | 3(27.3%) | |
ECOG Performance Status | |||
Score 0 | 92(71.8%) | 6(54.5%) | 0.387 |
Score 1 | 36(28.2%) | 5(45.5%) | |
BCLC Classification | |||
Grade B | 69(53.9%) | 6(54.5%) | 0.967 |
Grade C | 59(46.1%) | 5(45.5%) | |
Median size of the largest nodule(mm) | 64.5(34.3–103.0) | 103.0(56.0–140.0) | 0.078 |
WBC(x10^9/L) | 5.32 ± 2.32 | 5.10 ± 1.48 | 0.765 |
HB(g/L) | 128.70 ± 17.64 | 124.00 ± 14.68 | 0.472 |
PLT(x10^9/L) | 142.0(97.0–187.0) | 130.0(104.0–188.0) | 0.824 |
ALT(U/L) | 46.5(24.2–60.7) | 30.0(19.0–50.0) | 0.192 |
AST(U/L) | 51.0(33.0–79.2) | 28.0(22.0–90.0) | 0.181 |
TB(umol/L) | 15.1(10.6–22.0) | 14.7(12.0–16.0) | 0.582 |
ALB (g/L) | 37.30 ± 5.58 | 38.28 ± 5.03 | 0.578 |
PT(s) | 12.02 ± 1.99 | 11.56 ± 0.82 | 0.432 |
NLR | 2.54(1.61–3.74) | 3.98(2.07–12.70) | 0.023 |
Treatment Approach | |||
Targeted Therapy | 25(19.5%) | 1(9.1%) | 0.008 |
TACE | 14(10.9%) | 1(9.1%) | |
Targeted + Immunotherapy | 20(15.7%) | 7(63.6%) | |
TACE + Targeted + Immunotherapy | 69(53.9%) | 2(18.2%) |